VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares VistaGen Therapeutics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Earnings and Valuation
This table compares VistaGen Therapeutics and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VistaGen Therapeutics | $1.27 million | 8.50 | -$69.68 million | ($1.66) | -0.15 |
| Monte Rosa Therapeutics | $123.67 million | 9.59 | -$38.63 million | ($1.76) | -7.90 |
Monte Rosa Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
VistaGen Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for VistaGen Therapeutics and Monte Rosa Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 290.62%. Monte Rosa Therapeutics has a consensus price target of $28.50, indicating a potential upside of 105.04%. Given VistaGen Therapeutics’ higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Monte Rosa Therapeutics.
Summary
Monte Rosa Therapeutics beats VistaGen Therapeutics on 12 of the 15 factors compared between the two stocks.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
